← Companies|ObsEva (XOMA)
Ob

ObsEva (XOMA)

Geneva CHFounded 201230 employees
Private CapbiotechAcquiredWomen's Health
Platform: Linzagolix Gyn
Market Cap
N/A
All Drugs
4
Clinical Trials
10
Failed / Terminated
1
FDA Approved
2
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
SovazumabOBS-5255NDA/BLA1MultispecificIL-17ABCMA ADCSLEBCC
OBS-1037OBS-1037Preclinical1Fusion ProteinMDM2USP1iMDSFSGS
TixatenlimabOBS-6322Approved4Fusion ProteinGIP-RCAR-T CD19SCDUC
LirarelsinOBS-2472Approved4PeptideGIP-RMDM2iPancreatic CaMDS
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (9)
2025-01-11
Lirarelsin Ph3 Readout
Pancreatic Ca
Past
2025-11-14
Tixatenlimab Ph3 Readout
UC
Past
2026-10-26
Sovazumab Ph3 Readout
BCC
Ph3 Readout
2028-03-20
OBS-1037 Interim
FSGS
Interim
2029-02-18
Lirarelsin Ph3 Readout
Pancreatic Ca
Ph3 Readout
2029-03-17
Tixatenlimab Ph3 Readout
UC
Ph3 Readout
2030-10-12
Lirarelsin Ph3 Readout
Pancreatic Ca
Ph3 Readout
2030-10-17
Tixatenlimab Ph3 Readout
SCD
Ph3 Readout
2030-11-25
Tixatenlimab Ph3 Readout
UC
Ph3 Readout